132 related articles for article (PubMed ID: 34191969)
1. COVID-19 Pandemic Leading to the Accelerated Development of a Virtual Health Model for Isotretinoin.
Kane S; Admani S
J Dermatol Nurses Assoc; 2021; 13(1):54-57. PubMed ID: 34191969
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in isotretinoin prescriptions during the COVID-19 pandemic at a U.S. academic medical center.
Duan GY; Ruiz de Luzuriaga AM
Arch Dermatol Res; 2023 Apr; 315(3):643-645. PubMed ID: 36149480
[TBL] [Abstract][Full Text] [Related]
3. Contraceptive counseling for iPLEDGE and its burden on dermatologists.
Owens KE; Jiang SW; Nicholas MW
Arch Dermatol Res; 2024 May; 316(6):287. PubMed ID: 38805059
[TBL] [Abstract][Full Text] [Related]
4. Patient Access in Restrictive Risk Management Programs: The Case of iPLEDGE.
Kerr KW; Wosinska ME
Ther Innov Regul Sci; 2017 Jan; 51(1):16-23. PubMed ID: 30235995
[TBL] [Abstract][Full Text] [Related]
5. US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin.
Tkachenko E; Singer S; Sharma P; Barbieri J; Mostaghimi A
JAMA Dermatol; 2019 Oct; 155(10):1175-1179. PubMed ID: 31314041
[TBL] [Abstract][Full Text] [Related]
6. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
7. Ignoring the elephant in the room-overregulated isotretinoin and unregulated dietary supplements in the United States.
Zamil DH; Paidisetty PS; Wang LK
Proc (Bayl Univ Med Cent); 2022; 35(6):892-893. PubMed ID: 36304632
[TBL] [Abstract][Full Text] [Related]
8. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
9. A novel patient support program to address isotretinoin adherence: proof-of-concept analysis.
Eichenfield LF; Krakowski AC
J Drugs Dermatol; 2015 Apr; 14(4):375-9. PubMed ID: 25844611
[TBL] [Abstract][Full Text] [Related]
10. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
Honein MA; Lindstrom JA; Kweder SL
Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
[TBL] [Abstract][Full Text] [Related]
11. Falsification of at-home isotretinoin pregnancy testing during the COVID-19 pandemic: A case series and proposal of mitigation strategies.
Johnson H; Ranum A; Mansh M; Farah RS; Pearson DR
JAAD Case Rep; 2022 Oct; 28():49-53. PubMed ID: 35971550
[No Abstract] [Full Text] [Related]
12. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.
Charrow A; Xia FD; Lu J; Waul M; Joyce C; Mostaghimi A
PLoS One; 2019; 14(3):e0210445. PubMed ID: 30913210
[TBL] [Abstract][Full Text] [Related]
13. iPLEDGE Must Abstain from Abstinence.
Lowery K; Rosen T; Malek J
J Clin Aesthet Dermatol; 2020 Jun; 13(6):54-56. PubMed ID: 32884622
[TBL] [Abstract][Full Text] [Related]
14. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
[TBL] [Abstract][Full Text] [Related]
15. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
16. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis.
Lee YH; Scharnitz TP; Muscat J; Chen A; Gupta-Elera G; Kirby JS
JAMA Dermatol; 2016 Jan; 152(1):35-44. PubMed ID: 26630323
[TBL] [Abstract][Full Text] [Related]
17. Compliance with pregnancy prevention measures during isotretinoin therapy.
Collins MK; Moreau JF; Opel D; Swan J; Prevost N; Hastings M; Bimla Schwarz E; Korb Ferris L
J Am Acad Dermatol; 2014 Jan; 70(1):55-9. PubMed ID: 24157382
[TBL] [Abstract][Full Text] [Related]
18. Important controversies associated with isotretinoin therapy for acne.
Wolverton SE; Harper JC
Am J Clin Dermatol; 2013 Apr; 14(2):71-6. PubMed ID: 23559397
[TBL] [Abstract][Full Text] [Related]
19. Isotretinoin Monitoring Trends: A National Survey of Dermatologists.
Hobson JG; Cunningham MJ; Lesiak K; Lester EB; Tegeder AR; Zeeck E; Hugh JM; Lin JH
J Drugs Dermatol; 2017 Jun; 16(6):557-564. PubMed ID: 28686773
[TBL] [Abstract][Full Text] [Related]
20. Telehealth as a Bright Spot of the COVID-19 Pandemic: Recommendations From the Virtual Frontlines ("Frontweb").
Olayiwola JN; Magaña C; Harmon A; Nair S; Esposito E; Harsh C; Forrest LA; Wexler R
JMIR Public Health Surveill; 2020 Jun; 6(2):e19045. PubMed ID: 32479413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
